ImmunogenX enrolls patients for Solutions for Celiac trial of Latiglutenase

ImmunogenX, a subsidiary of Immunogenics, has started enrollment of patients for a phase 2b clinical trial to evaluate Latiglutenase (IMGX003), its lead candidate for the ... Read More